Cockrell Family Regent's Chair in Engineering #9
Cellular and Biomolecular Engineering
Phone: (512) 471-6975
Office: CPE 4.410
Since 2009 our laboratory has been focused on the discovery and development of protein therapeutics and on the analysis of adaptive immune responses.
Current projects include:
- Engineering and preclinical/clinical development of human enzyme therapeutics for cancer treatment.
- Development of methods for the molecular-level understanding of antibody responses to immune challenge.
- Analysis of the antibody repertoire elicited by viral infection (e.g. HIV-1) and vaccination to aid the development of more efficient vaccines.
- Engineering of antibody therapeutics displaying enhanced ability to recruit cytotoxic leukocytes and blood proteins (complement) for the effective clearance of pathogens.
Earlier work by the Georgiou lab had focused on redox homeostasis and protein biogenesis in bacteria and on the development of platform technologies for protein expression and engineering. These studies led to a number of mechanistic advances and to new technologies that are being used commercially for therapeutic protein manufacturing and protein engineering. Dr. Georgiou is co-inventor of 29 issued and 46 pending US patents. Notably, 16 different technology suites (comprising either one or multiple patents) have been licensed to majorepharmaceutical and biotechnology companies.